Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00446784 |
CE 224,535 is being developed for the treatment of rheumatoid arthritis. The purpose of this study is to evaluate the safety and tolerability of CE 224,535 after 4 weeks of treatment in subjects with rheumatoid arthritis already receiving methotrexate
Condition | Intervention | Phase |
---|---|---|
Arthritis, Rheumatoid |
Drug: CE-224,535 Drug: Methotrexate |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study |
Official Title: | A Phase 1, Double Blind Study Of The Safety And Pharmacokinetics Of Multiple Doses Of CE 224,535 In Subjects With Rheumatoid Arthritis Receiving Methotrexate |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
Pfizer Investigational Site | |
Ocala, Florida, United States, 34471 | |
Pfizer Investigational Site | |
Ocala, Florida, United States, 34474 | |
Pfizer Investigational Site | |
Miami, Florida, United States, 33169 | |
United States, Michigan | |
Pfizer Investigational Site | |
Kalamazoo, Michigan, United States, 49007 | |
United States, Pennsylvania | |
Pfizer Investigational Site | |
Ducansville, Pennsylvania, United States, 16635 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A6341006 |
Study First Received: | March 9, 2007 |
Last Updated: | October 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00446784 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Antimetabolites Autoimmune Diseases Immunologic Factors Joint Diseases Arthritis, Rheumatoid Rheumatic Diseases Folic Acid Antagonists |
Immunosuppressive Agents Folic Acid Musculoskeletal Diseases Arthritis Connective Tissue Diseases Methotrexate Antirheumatic Agents |
Antimetabolites Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Arthritis, Rheumatoid Reproductive Control Agents Musculoskeletal Diseases Arthritis Therapeutic Uses Abortifacient Agents Connective Tissue Diseases |
Methotrexate Dermatologic Agents Nucleic Acid Synthesis Inhibitors Autoimmune Diseases Immune System Diseases Joint Diseases Enzyme Inhibitors Rheumatic Diseases Abortifacient Agents, Nonsteroidal Folic Acid Antagonists Immunosuppressive Agents Pharmacologic Actions Antirheumatic Agents |